Janus-activated kinase 2 inhibitors: A new era of targeted therapies providing significant clinical benefit for philadelphia chromosome-negative myeloproliferative neoplasms

Research output: Contribution to journalEditorial

11 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)781-783
Number of pages3
JournalJournal of Clinical Oncology
Volume29
Issue number7
DOIs
StatePublished - Mar 1 2011

Fingerprint

Janus Kinase 2
Molecular Targeted Therapy
Philadelphia Chromosome
Myeloproliferative Disorders
Protein Kinase Inhibitors
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{91f29e4562a44de9bd67c00a91320271,
title = "Janus-activated kinase 2 inhibitors: A new era of targeted therapies providing significant clinical benefit for philadelphia chromosome-negative myeloproliferative neoplasms",
author = "Srdan Verstovsek",
year = "2011",
month = "3",
day = "1",
doi = "10.1200/JCO.2010.33.4508",
language = "English (US)",
volume = "29",
pages = "781--783",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Janus-activated kinase 2 inhibitors

T2 - A new era of targeted therapies providing significant clinical benefit for philadelphia chromosome-negative myeloproliferative neoplasms

AU - Verstovsek, Srdan

PY - 2011/3/1

Y1 - 2011/3/1

UR - http://www.scopus.com/inward/record.url?scp=79952335047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952335047&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.4508

DO - 10.1200/JCO.2010.33.4508

M3 - Editorial

C2 - 21220594

AN - SCOPUS:79952335047

VL - 29

SP - 781

EP - 783

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -